Peptide Therapeutics Forum @ Basel Life, 11.-12.09.19

  • Print

190417 PeptideTherapeuticsForum  BaselLife2019

Congress Center Basel, 10 - 11 September 2019 

Chairs  
Thomas Vorherr (Novartis Pharma AG, Basel, Switzerland)  
Roderich Süssmuth (Technical University of Berlin, Germany) 


Tuesday, 10 September 2019 

10.00 Playmolecule, a repository of deep learning based applications for biomolecule design 
Franck Chevalier (Acellera, Barcelona, Spain)
10.30 Optimization of the lipopeptide arylomycin natural product into Gram-negative antibiotics 
Christopher Heise (Genentech Research & Early Development, San Francisco, United States)
11.00 Break
11.30 Activation of the Hippo pathway via targeting of transcription factor TEAD using designed tertiary protein structure mimetics 
Helene Adihou (Astra Zeneca, Dortmund, Germany)
12.00 Elimination of Aβ oligomers by the orally available all-D-peptide PRI-002 reverses cognition deficits and decelerates neurodegeneration 
Dieter Willbold (University of Düsseldorf, Germany)
12.30 Lunch break and Industry Symposium
14.00 PLENARY LECTURE The chemical evolution of endocrine hormones 
Richard DiMarchi (University of Indiana, Bloomington, United States)
15.00 Break
15.30 Peptide platforms for therapy and imaging: The first total synthesis of amanitin for ADCs and one-step 18F-labeling PET-oncology 
David Perrin (University of British Columbia, Vancouver, Canada)
16.00 Virobiome derived anti-inflammatory short peptides
Michael Ruff (Creative BioPeptides)


Wednesday, 11 September 2019 

10.00 Exotic side chain-to-side-chain cyclization modes in octreotide analogs for tumor pretargeting
Anna Maria Papini (University of Florence, Italy)
10.30 Peptide-based radiopharmaceuticals for cancer imaging and therapy Agonist or Antagonist? Does it really matter?
Melpomeni Fani (University Hospital Basel, Switzerland)
11.00 Break
11.30 Vancomycin regains effectiveness for resistant bacteria by  conjugation to cationic peptides
Walter Mier (University of Heidelberg, Germany)
12.00 Peptide discovery at protagonist therapeutics: A platform yielding multiple clinical candidates
Mark Smythe (Protagonist, Newark, United States)
12.30 Lunch break and Industry Symposium
14.00 Disulfide-rich peptide production
Mike Pennington (AmbioPharm, North Augusta, United States)
14.30 A new green solvent for solid phase peptide synthesis
Jon Collins (CEM, Matthews, United States)
15.00 Break
15.30 Synthetic immune system engagers target cancer cells and  prevent tumor formation 
Christian Becker (University of Vienna, Austria)
16.00 Discovery and clinical development of an inhaled cyclic peptide elastase inhibitor for the treatment of cystic fibrosis 
Roxana Drake & Marc Thommen (Santhera Pharmaceuticals CH Ltd., Pratteln, Switzerland)


The programme indicated maybe subject to change!  

Website Basel Life: https://www.basellife.org/

 


David Spichiger, SCS
17.04.2019